Abstract
Bacterial infection is a very common complication in hematological neutropenic patients whose treatment is extremely challenging for several reasons. First, they are frequently caused by resistant pathogens (multidrug resistant (MDR)), and this may limit the availability of effective therapeutic weapons. Second, these patients often present peculiar pathophysiological conditions that may alter the pharmacokinetic behavior of antimicrobials, and this may explain the need for a new administration schedule and new dosing regimens of antibiotics in this setting. In an era in which there are only few new therapeutic weapons for the treatment of MDR bacterial infections, while advocating for new drugs, what could be effectively done nowadays is to increase the knowledge on appropriateness of the use of currently available drugs to improve clinical outcome and to preserve their activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
We are sorry, but there is no personal subscription option available for your country.
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bow EJ . Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 2009; 46: 259–268.
Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S et al. Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 2010; 27: 1037–1045.
Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sanchez-Ortega I et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66: 657–663.
Pea F, Viale P, Furlanut M . Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009–1034.
Udy AA, Roberts JA, Lipman J . Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7: 539–543.
Pea F, Viale P . Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock—does the dose matter? Crit Care 2009; 13: 214.
Pea F, Viale P . The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42: 1764–1771.
Craig WA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10.
Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005; 49: 3550–3553.
Lamoth F, Buclin T, Csajka C, Pascual A, Calandra T, Marchetti O . Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009; 53: 785–787.
Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME . Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 581–589.
Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C et al. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008; 8: 612–620.
Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332–339.
Moriyama B, Henning SA, Childs R, Holland SM, Anderson VL, Morris JC et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010; 44: 929–935.
Daikos GL, Markogiannakis A . Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135–1141.
Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM . Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999; 44: 235–242.
Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD . Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007; 51: 1787–1794.
Stewart PS, Davison WM, Steenbergen JN . Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2009; 53: 3505–3507.
Chaftari AM, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2010; 36: 182–186.
Infectious Diseases Society of America. The 10 × ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081–1083.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
FP received consulting fees from Astellas Pharma, Pfizer and Achaogen. FP also has been in the speaker bureau of Gilead, MSD Italy, Novartis, Pfizer and Sanofi Aventis.
Additional information
This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO—Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.
Rights and permissions
About this article
Cite this article
Pea, F. Antibiotic therapy in hematological neutropenic patients: what is the news?. Leukemia Suppl 1 (Suppl 2), S20–S21 (2012). https://doi.org/10.1038/leusup.2012.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/leusup.2012.13